ADGM
Adagio Medical Holdings, Inc.
Medical - Devices
Market Cap$15M
5Y Perf.-81.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ADGM vs BEAT
Revenue, margins, valuation, and 5-year total return — side by side.
BEAT
HeartBeam, Inc.
Medical - Healthcare Information Services
Market Cap$35M
5Y Perf.-63.0%
ADGM vs BEAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ADGM | BEAT |
|---|---|---|
| Industry | Medical - Devices | Medical - Healthcare Information Services |
| Market Cap | $15M | $35M |
| Revenue (TTM) | $-143K | $0.00 |
| Net Income (TTM) | $-75M | $-21M |
| Gross Margin | -6.2% | — |
| Operating Margin | -232.3% | — |
| Total Debt | $16M | $0.00 |
| Cash & Equiv. | $21M | $4M |
ADGM vs BEAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ADGM
BEAT
| Stock | Aug 24 | May 26 | Return |
|---|---|---|---|
| Adagio Medical Hold… (ADGM) | 100 | 18.5 | -81.5% |
| HeartBeam, Inc. (BEAT) | 100 | 37.0 | -63.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADGM vs BEAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ADGM leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ADGM
Adagio Medical Holdings, Inc.
The Income Pick
ADGM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.87
- Rev growth -10.3%, EPS growth 27.2%, 3Y rev CAGR -0.1%
- Lower volatility, beta 0.87, Low D/E 81.7%, current ratio 3.27x
Best for: income & stability and growth exposure
BEAT
HeartBeam, Inc.
The Long-Run Compounder
BEAT is the clearest fit if your priority is long-term compounding.
- -81.4% 10Y total return vs ADGM's -89.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ADGM | -10.3% revenue growth vs BEAT's -100.0% |
| Stability / Safety | ADGM | Beta 0.87 vs BEAT's 1.24 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ADGM | -26.1% vs BEAT's -53.7% |
| Efficiency (ROA) | ADGM | -189.8% ROA vs BEAT's -353.1% |
ADGM vs BEAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2019
ADGM vs BEAT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBEATLAGGINGADGM
ADGMAdagio Medical Holdin…
1leads
BEATHeartBeam, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ADGMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BEAT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BEAT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
BEAT4/6
Risk & VolatilityBeta, volatility, and downside exposure
ADGM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BEAT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BEAT and ADGM operate at a comparable scale, with $0 and -$143,000 in trailing revenue.
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| RevenueTrailing 12 months | -$143,000 | $0 |
| EBITDAEarnings before interest/tax | -$67M | -$21M |
| Net IncomeAfter-tax profit | -$75M | -$21M |
| Free Cash FlowCash after capex | -$24M | -$15M |
| Gross MarginGross profit ÷ Revenue | -6.2% | — |
| Operating MarginEBIT ÷ Revenue | -232.3% | — |
| Net MarginNet income ÷ Revenue | -199.9% | — |
| FCF MarginFCF ÷ Revenue | -115.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -106.3% | +22.2% |
BEAT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ADGM and BEAT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| Market CapShares × price | $15M | $35M |
| Enterprise ValueMkt cap + debt − cash | $10M | $31M |
| Trailing P/EPrice ÷ TTM EPS | -0.27x | -1.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 54.49x | — |
| Price / BookPrice ÷ Book value/share | 0.73x | 11.27x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ADGM and BEAT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BEAT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
BEAT delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-8 for ADGM. On the Piotroski fundamental quality scale (0–9), ADGM scores 4/9 vs BEAT's 1/9, reflecting mixed financial health.
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -7.5% | -5.7% |
| ROA (TTM)Return on assets | -189.8% | -3.5% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -374.1% | -4.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.82x | — |
| Net DebtTotal debt minus cash | -$4M | -$4M |
| Cash & Equiv.Liquid assets | $21M | $4M |
| Total DebtShort + long-term debt | $16M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -36.69x | — |
BEAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
BEAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BEAT five years ago would be worth $1,856 today (with dividends reinvested), compared to $1,053 for ADGM. Over the past 12 months, ADGM leads with a -26.1% total return vs BEAT's -53.7%. The 3-year compound annual growth rate (CAGR) favors BEAT at -25.8% vs ADGM's -52.8% — a key indicator of consistent wealth creation.
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | -64.2% |
| 1-Year ReturnPast 12 months | -26.1% | -53.7% |
| 3-Year ReturnCumulative with dividends | -89.5% | -59.1% |
| 5-Year ReturnCumulative with dividends | -89.5% | -81.4% |
| 10-Year ReturnCumulative with dividends | -89.5% | -81.4% |
| CAGR (3Y)Annualised 3-year return | -52.8% | -25.8% |
BEAT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ADGM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ADGM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than BEAT's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADGM currently trades 36.9% from its 52-week high vs BEAT's 21.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.24x |
| 52-Week HighHighest price in past year | $2.58 | $4.00 |
| 52-Week LowLowest price in past year | $0.74 | $0.54 |
| % of 52W HighCurrent price vs 52-week peak | +36.9% | +21.8% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 124K | 1.6M |
ADGM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ADGMAdagio Medical Ho… | BEATHeartBeam, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BEAT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ADGM leads in 1 (Risk & Volatility). 1 tied.
Best OverallHeartBeam, Inc. (BEAT)Leads 3 of 6 categories
Loading custom metrics...
ADGM vs BEAT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — ADGM or BEAT?
Over the past 5 years, HeartBeam, Inc.
(BEAT) delivered a total return of -81. 4%, compared to -89. 5% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: BEAT returned -81. 4% versus ADGM's -89. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ADGM or BEAT?
By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.
(ADGM) is the lower-risk stock at 0. 87β versus HeartBeam, Inc. 's 1. 24β — meaning BEAT is approximately 43% more volatile than ADGM relative to the S&P 500.
03Which is growing faster — ADGM or BEAT?
On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc.
grew EPS 27. 2% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — ADGM or BEAT?
HeartBeam, Inc.
(BEAT) is the more profitable company, earning 0. 0% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BEAT leads at 0. 0% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — BEAT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ADGM or BEAT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ADGM or BEAT better for a retirement portfolio?
For long-horizon retirement investors, Adagio Medical Holdings, Inc.
(ADGM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (ADGM: -89. 5%, BEAT: -81. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ADGM and BEAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.